Chronic Myeloid Leukemia, Version 1.2019, Clinical Practice Guidelines in Oncology Journal Article


Authors: Radich, J. P.; Deininger, M.; Abboud, C. N.; Altman, J. K.; Berman, E.; Bhatia, R.; Bhatnagar, B.; Curtin, P.; DeAngelo, D. J.; Gotlib, J.; Hobbs, G.; Jagasia, M.; Kantarjian, H. M.; Maness, L.; Metheny, L.; Moore, J. O.; Pallera, A.; Pancari, P.; Patnaik, M.; Purev, E.; Rose, M. G.; Shah, N. P.; Smith, B. D.; Snyder, D. S.; Sweet, K. L.; Talpaz, M.; Thompson, J.; Yang, D. T.; Gregory, K. M.; Sundar, H.
Article Title: Chronic Myeloid Leukemia, Version 1.2019, Clinical Practice Guidelines in Oncology
Abstract: Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9; 22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient's age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.
Keywords: imatinib; tyrosine kinase inhibitors; minimal residual disease; chronic myelogenous leukemia; cytogenetic response; in-situ hybridization; complete; patients receiving imatinib; imatinib mesylate therapy; standard-dose; subcutaneous omacetaxine mepesuccinate; chromosome-negative metaphases
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 16
Issue: 9
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2018-09-01
Start Page: 1108
End Page: 1135
Language: English
ACCESSION: WOS:000443581300010
DOI: 10.6004/jnccn.2018.0071
PROVIDER: wos
PUBMED: 30181422
Notes: Review -- Source: Wos
Altmetric Score
MSK Authors
  1. Ellin Berman
    84 Berman